DOT1L
MOLECULAR TARGETDOT1 like histone lysine methyltransferase
DOT1L (DOT1 like histone lysine methyltransferase) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting DOT1L
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | sinefungin | 3.74 | 41 |
| 2 | iodotubercidin | 3.30 | 26 |
| 3 | sangivamycin | 3.00 | 19 |
| 4 | s adenosylhomocysteine | 2.40 | 10 |
| 5 | Cyproheptadine | 0.69 | 1 |
About DOT1L as a Drug Target
DOT1L (DOT1 like histone lysine methyltransferase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented DOT1L interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
DOT1L inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.